The US regulator has cleared the new 8 mg formulation of Eylea (aflibercept) for patients with wet age-related macular degeneration (AMD), diabetic macular oedema (DME), and diabetic retinopathy ...

Approval for Eylea for diabetic retinopathy was based on six-month and one-year trial results from PANORAMA, a phase 3 trial that enrolled 402 patients comparing the drug with placebo.

Eylea, which is used to treat age-related macular degeneration, brought in roughly $9.4 billion in sales last year, down a ...

The treatment is a biosimilar that could compete with Regeneron Pharmaceuticals’ Eylea. Teva and Alvotech have been working together in a strategic partnership since 2020. Teva Pharmaceutical ...

Additionally, patients who switched from EYLEA (aflibercept) Injection 2 mg to EYLEA HD at the beginning ... dosing interval of ≥4 months, with 40% and 24% having a last assigned dosing interval ...

In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg.

Bayer has submitted an application to the European Medicines Agency (EMA) to expand treatment intervals of up to 6 months with Eylea 8 mg (aflibercept 8 mg, 114.3 mg/ml solution for injection) for the ...